Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment.
2004; National Institutes of Health; Volume: 24; Issue: 3b Linguagem: Inglês
Autores
Floris M Wachters, Winette T.A. van der Graaf, Harry J.M. Groen,
Tópico(s)Lung Cancer Treatments and Mutations
ResumoOne of the major dose-limiting toxicities of anthracyclines is cardiotoxicity due to irreversible cardiomyopathy. Whether cisplatin-based treatment induces caridiotoxicity in the short term, especially in non-small cell lung cancer (NSCLC) patients with cardiovascular comorbidity, has not been studied previously. The aim of this study was to evaluate cardiotoxicity in advanced NSCLC patients receiving cisplatin-gemcitabine (CG) or epirubicin-gemcitabine (EG) as first-line treatment.Patients were randomised to receive gemcitabine 1125 mg/m2 (days 1 and 8) plus either cisplatin 80 mg/m2 (day 2) or epirubicin 100 mg/m2 (day 1) every 3 weeks for a maximum of 5 cycles. Patients had to have a left ventricular ejection fraction (LVEF) > 45%, measured by multiple gated acquisition (MUGA) scan. A second MUGA scan was performed 12 weeks after the end of treatment.Sixty-nine patients were included. The mean total dose of cisplatin was 349 mg/m2 and of epirubicin 452 mg/m2. The mean difference in decline in LVEF from baseline was 2% in the CG arm versus 6% in the EG arm (p=0.016). Clinically evident cardiac failure was not observed during 12 months follow-up. No correlation was found with total drug doses administered. In patients with a history of cardiac disease a trend towards a higher decrease in LVEF was observed.Although in the EG arm the LVEF significantly declined and in the CG arm a trend for LVEF to decline was observed, the risk of cardiac failure is limited in advanced NSCLC patients.
Referência(s)